[go: up one dir, main page]

AR027122A1 - Composicion paa el tratamiento de tejidos danados - Google Patents

Composicion paa el tratamiento de tejidos danados

Info

Publication number
AR027122A1
AR027122A1 ARP000106960A ARP000106960A AR027122A1 AR 027122 A1 AR027122 A1 AR 027122A1 AR P000106960 A ARP000106960 A AR P000106960A AR P000106960 A ARP000106960 A AR P000106960A AR 027122 A1 AR027122 A1 AR 027122A1
Authority
AR
Argentina
Prior art keywords
treatment
composition
donated
fabrics
wound
Prior art date
Application number
ARP000106960A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR027122A1 publication Critical patent/AR027122A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curacion) de tejidos danados, tal como una herida, comprendiendo el agentefarmacéutico una composicion que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y , opcionalmente (c) un vehículo, diluyente o excipientefarmacéuticamente aceptable; pudiendo el agente inhibidor inhibir la accion de al menos una porteína adversa específica (por ejemplo, una proteasa específica)que está regulada positivamente en un entorno de tejido danado, tal como una herida.
ARP000106960A 1999-12-29 2000-12-27 Composicion paa el tratamiento de tejidos danados AR027122A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
AR027122A1 true AR027122A1 (es) 2003-03-12

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106960A AR027122A1 (es) 1999-12-29 2000-12-27 Composicion paa el tratamiento de tejidos danados

Country Status (12)

Country Link
EP (1) EP1242120A2 (es)
JP (1) JP2003519193A (es)
AR (1) AR027122A1 (es)
AU (1) AU1878201A (es)
CA (1) CA2395487A1 (es)
CO (1) CO5271671A1 (es)
EC (1) ECSP003859A (es)
GB (1) GB9930768D0 (es)
GT (1) GT200000224A (es)
PE (1) PE20011095A1 (es)
UY (1) UY26514A1 (es)
WO (1) WO2001049309A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE389719T1 (de) 2000-10-16 2008-04-15 Genentech Inc Behandlungsverfahren mit wisp-polypeptiden
DK1414487T3 (da) * 2001-07-27 2006-10-09 Orthologic Corp Anvendelse af thrombin-peptidderivater til behandling af kroniske hudsår
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
AU2003256343B2 (en) 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
DK1559431T3 (da) 2003-12-31 2007-07-30 Orthologic Corp Farmaceutisk sammensætning til thrombinpeptidderivater
US8106176B2 (en) 2005-10-07 2012-01-31 Instituto di Richerche di Biologia Molecolare P. Angeletti SpA Matrix metalloproteinase 11 vaccine
KR20150072458A (ko) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
KR101629504B1 (ko) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 사이토카인 조합을 함유하는 피부 상태 개선용 조성물
KR102544139B1 (ko) * 2017-04-21 2023-06-15 프레시전 인코포레이티드 피부 경화증의 치료를 위한 매트릭스 금속단백분해효소를 포함하는 자가 유래 세포의 전달

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (ja) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd 新規外用組成物
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
GT200000224A (es) 2002-06-15
AU1878201A (en) 2001-07-16
ECSP003859A (es) 2002-09-27
EP1242120A2 (en) 2002-09-25
WO2001049309A3 (en) 2002-02-28
CA2395487A1 (en) 2001-07-12
CO5271671A1 (es) 2003-04-30
JP2003519193A (ja) 2003-06-17
PE20011095A1 (es) 2001-10-27
GB9930768D0 (en) 2000-02-16
UY26514A1 (es) 2001-07-31
WO2001049309A2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
BR0015605A (pt) Composição e uso
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
ES2159591T3 (es) Composicion de liberacion controlada.
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0116084A (pt) Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio
AR007582A1 (es) Composicion para el lavado de la piel, procedimiento para prepararla y el uso de la misma para la fabricacion de medicamentos dado el caso, para eltratamiento cosmetico de la piel.
AR027122A1 (es) Composicion paa el tratamiento de tejidos danados
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
MD2550C2 (ro) Preparat antibiotic cu eliberare lenta a ingredientului activ şi utilizare a acestuia
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
CO5271686A1 (es) Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico
ES2179658T3 (es) Uso de oxazolidinonas para la preparacion de un medicamento de suministro transdermico.
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal